Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The current pain caused by the high cost of the GLP-1 agonist anti-obesity drugs will pass. Prachi Patkee and other analysts ...

Adults With Obesity More Likely to Ration Drugs to Save Money. Adults with obesity are more likely to ration their ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

(HealthDay News) — Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert ...

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

Cleveland Clinic expert discusses treatment options for obesity including weight loss drugs and bariatric surgery.